

## COMPANY OVERVIEW

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. The Company is headquartered in Victoria, BC and focuses its development efforts globally.

## RECENT NEWS

### Aurinia Reports First Quarter Financial Results and Operational Highlights

May 10 2018, 4:02 PM EDT

### Aurinia Pharmaceuticals Recognizes World Lupus Day™ with Activities Focused on Raising Awareness of Lupus Nephritis

May 10 2018, 8:00 AM EDT

### Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018

May 1 2018, 4:23 PM EDT

## STOCK OVERVIEW

Symbol	AUPH
Exchange	NASDAQ
Market Cap	490.86m
Last Price	\$5.84
52-Week Range	\$4.41 - \$7.68

## INVESTOR RELATIONS

Celia Economides  
Vice President, Public Affairs  
[IR@auriniapharma.com](mailto:IR@auriniapharma.com)

## MANAGEMENT TEAM

**Richard M. Glickman, L.L.D. (Hon)**  
CEO & Chairman of the Board

**Neil Solomons, M.D.**  
Chief Medical Officer

**Michael Martin**  
Chief Operating Officer

**Dennis Bourgeault**  
Chief Financial Officer

**Robert Huizinga, Ph.D., R.N., CNeph(C)**  
Executive Vice President, Corporate Development

**Erik Eglite, D.P.M., J.D., M.B.A.**  
Senior Vice President, General Counsel & Chief Corporate Compliance Officer

**Rashieda Gluck**  
Senior Vice President, Global Clinical Operations

**Ron Demers**  
Vice President, Manufacturing and Supply Chain

**Celia Economides**  
Vice President, Corporate & Public Affairs

**Lawrence (Larry) D. Mandt**  
Vice President, Quality & Regulatory Affairs

**Bradley J. Dickerson**  
General Manager, Americas & Global Commercial Lead

**Simrat Randhawa, M.D., M.B.A.**  
Head of Global Medical Affairs

## AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street  
Victoria, BC V8Z 7X8  
Canada

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand

name are the property of their respective companies.